Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients

BMC Nephrology

Research Article

Saideep Bose¹  Hai V. Nguyen²  Eric Finkelstein² 

[1] Division of Cardiac, Thoracic, and Vascular Surgery, National University Hospital, 5 Lower Kent Ridge Road, 119074, Singapore, Singapore;Program in Health Services and Systems Research, Duke-NUS Medical School, 8 College Road, 169857, Singapore, Singapore;

关键词: Sevelamer;    Calcium carbonate;    Dialysis;    Hyperphosphatemia;    Chronic kidney disease;    Cost-effectiveness;   

DOI  :  10.1186/s12882-016-0256-0

 received in 2015-08-20, accepted in 2016-04-21,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundSevelamer is an alternative to calcium carbonate for the treatment of hyperphosphatemia among non-dialysis dependent patients with chronic kidney disease (CKD). Although some studies show that it may reduce mortality and delay the onset of dialysis when compared to calcium carbonate, it is also significantly more expensive. Prior studies looking at the incremental cost-effectiveness of sevelamer versus calcium carbonate in pre-dialysis patients are based on data from a single clinical trial. The goal of our study is to use a wider range of clinical data to achieve a more contemporary and robust cost-effectiveness analysis.MethodsWe used a Markov model to estimate the lifetime costs and quality-adjusted life years (QALYs) gained for treatment with sevelamer versus calcium carbonate. The model simulated transitions among three health states (CKD not requiring dialysis, end-stage renal disease, and death). Data on transition probabilities and utilities were obtained from the published literature. Costs were calculated from a third party payer perspective and included medication, hospitalization, and dialysis. Sensitivity analyses were also run to encompass a wide range of assumptions about the dose, costs, and effectiveness of sevelamer.ResultsOver a lifetime, the average cost per patient treated with sevelamer is S$180,724. The estimated cost for patients treated with calcium carbonate is S$152,988. A patient treated with sevelamer gains, on average, 6.34 QALYs relative to no treatment, whereas a patient taking calcium carbonate gains 5.81 QALYs. Therefore, sevelamer produces an incremental cost-effectiveness ratio (ICER) of S$51,756 per QALY gained relative to calcium carbonate.ConclusionBased on established benchmarks for cost-effectiveness, sevelamer is cost effective relative to calcium carbonate for the treatment of hyperphosphatemia among patients with chronic kidney disease initially not on dialysis.

【 授权许可】

CC BY   
© Nguyen et al. 2016